First AD

Second AD

Treatment Flexibility While on Abrocitinib in Atopic Dermatitis (JADE REGIMEN)

Video content above is prompted by the following:

Please discuss data with oral JAK inhibitors as maintenance and rescue treatments.

Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Atopic Dermatitis

INC-22-MDD0529 - /clinical/atopic-dermatitis

Atopic Dermatitis condition center page, resources on the topics of medical news and expert insight into eczema can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Advances in Oral Systemic Treatments for Management of Atopic Dermatitis

Oral JAK inhibitors have emerged as promising agents in the management of various inflammatory and autoimmune conditions. As maintenance therapy, they offer a convenient oral administration route, potentially improving patient adherence compared to injectable biologics. These inhibitors target specific pathways involved in inflammation, providing a tailored approach to disease management. In rescue treatment scenarios, oral JAK inhibitors can rapidly modulate immune responses, offering a valuable option for patients experiencing disease flares. Ongoing research continues to refine their safety profile and optimize their therapeutic potential.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.